Remote patient monitoring reimbursement Market Outlook 2026–2033: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines remote patient monitoring, the use of connected devices, software and clinical staff to track the health of patients with chronic conditions outside the clinic. It tests how far payment changes and device data integration can move the market from fee per code billing toward outcome-aligned chronic care by 2033.

Payment thresholds have been lowered. For 2026 the Medicare physician fee schedule added CPT 99445 for device supply when a patient transmits readings on 2 to 15 days a month and CPT 99470 for 10 to 19 minutes of monthly clinical management, against earlier thresholds of 16 days and 20 minutes. The conclusion is that practices can bill for patients who use devices less often, which widens the number of patients who can be enrolled and billed.

Evidence supports the economics for providers. A 2025 Health Affairs study of 754 primary care practices found Medicare revenue 20% higher at practices that adopted remote monitoring than at matched controls, with about 12.4% of the increase from direct monitoring billing and roughly 25% from additional visits and downstream testing. The conclusion is that adoption pays through the wider care relationship, not only through monitoring codes.

The payment model is changing. CMS announced the ACCESS model in December 2025, a voluntary 10-year model that pays participants outcome-aligned fixed payments tied to clinical goals such as lower blood pressure, across four condition tracks, with 150 accepted participants reported ahead of the planned July 2026 launch. The conclusion is that devices and software will be judged on health results as well as on billed days, which favours platforms that connect device data to the care team.

The brief treats remote patient monitoring as an accelerating signal with a seven year horizon to 2033. It identifies which device and platform makers move first and what each means for providers, payers and technology companies. It is a focused 113-page decision brief that presents an indicative trajectory rather than a segmented market model.

Remote patient monitoring sends readings from a device in the home, such as a blood pressure cuff, glucose sensor or cardiac patch, to a platform that a clinical team reviews. When readings move outside agreed limits the team calls the patient or changes treatment. The model is built for chronic conditions, where small changes between visits shape outcomes.

Payment decides how many patients are enrolled. The 2026 codes pay a national average of USD 48 for device supply on 2 to 15 days of readings, the same as the existing code for 16 days or more, and USD 26 for 10 to 19 minutes of management. No existing monitoring or chronic care management codes were removed or reduced. The conclusion is that billing now follows how patients actually use devices, and patients who were once left out of billing can be enrolled.

The payment model is moving from code billing to outcomes. ACCESS pays participants fixed instalments tied to clinical benchmarks across cardiometabolic, cardio-kidney-metabolic, musculoskeletal and behavioral health tracks, and the full payment is earned only when patients meet measurable goals. The conclusion is that monitoring becomes a tool inside a managed care programme, and the participants range from technology companies to medical groups.

Device makers and platform companies are already inside the model. The list of accepted ACCESS participants includes Welldoc, Withings, WHOOP, Verily, Aledade, DocGo and a cardiology group working with AliveCor. The conclusion is that makers of devices and software are entering care delivery directly, and partnerships between device and care teams will define the leaders.

The limits are billing and audit risk, alert fatigue, patient adherence and the lack of a single standard for device data in health records. The brief tests each limit against the cost trajectory to 2033.

The remote patient monitoring market, covering connected monitoring devices, monitoring platforms and software, and clinical monitoring services used for chronic care outside the hospital, and excluding hospital bedside monitoring, consumer fitness trackers sold without clinical services and telehealth visits, is valued at USD 10.0–14.0 billion in 2026 and is projected to reach USD 25.02–35.03 billion by 2033, at a CAGR of 14%.

The 2026 base rests on billed monitoring in the United States, together with smaller sales in Europe and Asia. Growth then follows the lower billing thresholds, the spread of outcome-aligned payment and the integration of device data into health records.

The forecast is sensitive to audit and billing rules, the results of the ACCESS model and the pace at which commercial payers follow Medicare.

The base case assumes ACCESS results support wider outcome-aligned payment, bringing the inflection to about 2028 and a 2033 value near the middle of the range. An accelerated case assumes strong ACCESS results and quick commercial payer adoption, bringing the inflection to 2027 and lifting the 2033 value to the top of the range. A delayed case assumes tighter audit rules and weak adherence, moving the inflection to 2031 and holding growth at the bottom of the range.

Growth drivers

• Chronic disease prevalence.
• Patients needing continuous oversight.
• Outcomes against standard care.
• Wider conditions.

Enablers

• Device data integration.
• Cellular and wearable devices.
• Payment and registry evidence.
• Provider programmes.

Restraints and barriers

• Patient engagement and adherence limits.
• Enrolment and staffing capacity.
• Billing and audit risk.
• Alert fatigue.

The direction of remote patient monitoring is set by Medicare payment rules, chronic disease burden, device and data integration advances, outcome evidence and the capacity of clinical staff to review readings.

The key participants in remote patient monitoring include Koninklijke Philips N.V., Medtronic plc, Masimo Corporation, OMRON Corporation, iRhythm Technologies, Inc., Dexcom, Inc., Abbott Laboratories, Withings SA, Welldoc, Inc., Teladoc Health, Inc., Omada Health, Inc., AliveCor, Inc., WHOOP, Inc., Alphabet Inc., DocGo Inc., Aledade, Inc., Epic Systems Corporation, Oracle Corporation, Apple Inc., Samsung Electronics Co., Ltd., GE HealthCare Technologies Inc., Boston Scientific Corporation, Baxter International Inc., Becton, Dickinson and Company, Validic, Inc., UnitedHealth Group Incorporated, Elevance Health, Inc., CVS Health Corporation, Humana Inc., Cigna Group, Kaiser Foundation Health Plan, Inc., Mayo Clinic, Cleveland Clinic, the American Medical Association, the American Heart Association, Inc., the American Diabetes Association, the Centers for Medicare & Medicaid Services and the Food and Drug Administration.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as outcome-aligned payment grows.

Philips, Medtronic, Masimo, OMRON and Abbott lead among established makers, Welldoc, Omada, Teladoc and Aledade lead among platforms and care companies, and Apple, Samsung and Alphabet bring consumer devices and data. Competitive intensity is high, with established device makers, platform companies and consumer technology companies all active.

Where value migrates.

In 2026 value sits with device supply and billed monitoring services, because the codes pay for days of readings and minutes of review. By 2028 it moves toward platforms that connect device data to the care team and earn outcome-aligned payments. By 2033 it settles with remote monitoring as a standard part of chronic care, where outcome data, record integration and payer contracts carry the margin. Margins hold for platforms with outcome data and narrow for makers of single devices sold on billed days.

The signals converge on a market where payment is widening and moving toward outcomes. New Medicare codes, the ACCESS model and evidence of higher practice revenue support growth, while billing and audit risk, alert fatigue and patient adherence hold back adoption.

Structural limits show where progress could slow: clinical staffing, patient engagement, record integration and commercial payer decisions. The brief therefore tracks four indicators: enrolled patients per year, ACCESS results, commercial payer contracts and device data integration.

Wider billing first, then outcome-aligned payment and wider conditions, then standard option status is the expected order of change.